Sfoglia per AUTORE
DORFF T
Collezione ASL Torino 4
Items : 2
Patient-reported Outcomes in Men with Metastatic Castration-resistant Prostate Cancer Harboring DNA Damage Response Alterations Treated with Talazoparib: Results from TALAPRO-1. in European urology / Eur Urol. 2023 Apr;83(4):352-360. doi: 10.1016/j.eururo.2022.05.030. Epub 2022 Jun 22.
2023
ASL Torino 4
AOU San Luigi di Orbassano
ASL Torino 4
AOU San Luigi di Orbassano
Niyazov A; Arondekar B; Healy C; Bhattacharyya H; Gurney H; Higano CS; Maruzzo M; Renard V; Machiels JP; Scagliotti G; Stirling A; Mehra N; Barthélémy P; Dorff T; Fizazi K; de Bono J; Saad F;
TALAPRO-1: Talazoparib monotherapy in metastatic castration-resistant prostate cancer (mCRPC) with tumor DNA damage response alterations (DDRm)-Exploration of germline DDR alteration landscape and potential associations with antitumor activity in Journal of Clinical Oncology
2022
ASL Torino 4
ASL Torino 4
Dorff TB; Fizazi K; Laird D; Barthélémy P; Delva R; Maruzzo M; Stirling A; MacHiels J-PH; Dumez H; Renard V; Hopkins J; Albacker LA; Chen H-C; Healy CG; Chelliserry J; Van Oort IM; Scagliotti GV; De Bono JS; Mehra N;